<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238039</url>
  </required_header>
  <id_info>
    <org_study_id>5826-18-SMC</org_study_id>
    <nct_id>NCT04238039</nct_id>
  </id_info>
  <brief_title>Ketamine Long Therm Follow Up Study</brief_title>
  <acronym>ket_Fol_Up</acronym>
  <official_title>Five Years Follow up: Add on Intravenous Ketamine for Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Chaim Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Chaim Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Results of the study and of 5 years follow up of depressed patients who participated in the
      study during 2014-2015. We will locate the participants and will interview them will use the
      same questionnaires to evaluate their depressive symptoms. We will also measure the time to
      relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anamnestic data will be collected from the patients, in addition, depressive symptoms will be
      measured using Montgomery Asberg Depression Scale (MADRAS). In addition, the Clinical Global
      Severity Scale (CGI-S) and Clinical Global Improvement (CGI-I) were performed 2 hours after
      treatment. In addition, we performed to prolong the time to relapse in this patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Medications</description>
  </primary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Followin Ketamine Treatment</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in the ketamine study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants in the ketamine study

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Revital Amiaz</name>
      <address>
        <city>Ramat Gan</city>
        <state>RI</state>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Revital Amiaz, MD</last_name>
      <phone>0542378757</phone>
      <email>amiazr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bat Chen Shlomy</last_name>
      <phone>+97235303350</phone>
      <email>revital.amiaz@sheba.health.gov.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 18, 2020</last_update_submitted>
  <last_update_submitted_qc>January 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Chaim Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Revital Amiaz</investigator_full_name>
    <investigator_title>Head of Psychiatry Department B</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder, ketamine, follow up, relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

